Showing results (771-780 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|April 27, 2025
HIV prevention and undiagnosed infections in children in sub-Saharan AfricaSouleymane Tassembedo, Nicolas Meda, Chipepo Kankasa, et al.
The Lancet. HIV|March 15, 2025
Safety, tolerability, and acceptability of long-acting injectable cabotegravir for HIV prevention in cisgender female adolescents (HPTN 084-01): a single-arm, open-label, phase 2b trialLynda Stranix-Chibanda, Erica L Hamilton, Julie Ngo, et al.
The Lancet. HIV|May 30, 2024
Critical illness due to infection in people living with HIVGuy A Richards, Jarrod Zamparini, Ismail Kalla, et al.
The Lancet. HIV|May 13, 2024
Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trialSerge P Eholie, Didier K Ekouevi, Corine Chazallon, et al.
The Lancet. HIV|December 1, 2025
Parkinsonism in people with virally suppressed HIVEran F Shorer, Raha M Dastgheyb, Leah H Rubin, et al.
The Lancet. HIV|May 11, 2024
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trialJean-Michel Molina, Giuliano Rizzardini, Catherine Orrell, et al.
The Lancet. HIV|May 11, 2024
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trialAnthony M Mills, Giuliano Rizzardini, Moti N Ramgopal, et al.
The Lancet. HIV|December 23, 2023
Prophylactic HIV-1 vaccine trials: past, present, and futureJoseph P Nkolola, Dan H Barouch
The Lancet. HIV|December 23, 2023
A community-based child health and parenting intervention to improve child HIV testing, health, and development in rural Lesotho (Early Morning Star): a cluster-randomised, controlled trialMark Tomlinson, Marguerite Marlow, Jackie Stewart, et al.
The Lancet. HIV|September 23, 2021
Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortiumLoveleen Bansi-Matharu, Andrew Phillips, Cristiana Oprea, et al.
Pageof 79